Investornewsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data On GITR Agonist KROS 101 At AACR-JCA Conference

(MENAFN- Investor Brand Network) Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference. The study demonstrated that KROS 101 enhances T cell infiltration, proliferation, and tumor-killing ability in melanoma and glioblastoma models while reducing regulatory T-cell suppression. Compared to the GITR antibody TRX518, KROS 101 showed superior tumor reduction in a human GITR knock-in mouse model. The company sees potential for the therapy to expand T cell responses and improve cancer treatment, supporting further clinical development.

To view the full press release, visit

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit the company's website at .

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company's newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN06022025000224011066ID1109177579